Unsatisfactory results derived from the use of MET inhibitors such as cabozantinib (abnormal MET activation has been found in 12%–58% of iCCAs) PI3K/AKT/mTOR inhibitors showed exiguous responses despite 12.5% of gallbladder cancers displaying activated mutations of PIK3CA. Here, MTOR is linked to gallbladder cancer.